Semagllutide ke sethuse sa glucose-sehlōhō se tsoetseng pele ka norvost bakeng sa kalafo ea lefu la tsoekere la 2. Ka June 2021, FDA e ile ea amohela Semagllutide ea Semaglide ea ho bapatsa e le lithethefatsi tse talang boima ba 'mele (lebitso la khoebo wgovy). Setlhare ke sethethefatsi se kang sa pele se ka se utloisang bohloko, se ka fokotsa thuso, 'me ka hona fokotsa ho ja lijo le khalori.
Ntle le ho sebelisoa ho phekola lefu la tsoekere ea tsoekere le botenya, ho ile ha fumanoa hore batho ba bangata ba lefu la ho tšoara bophelo bo botle ba pelo, ba fokotsa kotsi ea mofetše, 'me u thuse ho khaotsa. Ntle le moo, lithuto tse peli tsa morao tjena li bontšitse hore Semaglturide a ka fokotsa kotsi ea ho tšoaroa ke liphio tse sa feleng le lefu la Alzheimer.
Boithuto ba pejana bo bontšitse hore ho fokotsa boima ba mangole o ka imolla matšoao a mangole a mangoesritis (ho kenyeletsa le phomolo ea bohloko). Leha ho le joalo, litlamorao tsa GLP-1 Receptor Boima ba 'mele ba ho lahleheloa ke semagontor bo joalo ka Semaa Hours
Ka la 30 Mphalane, 2024, bafuputsi ba tsoang Univesithing ea Copenhagen le Novo Norrifritis ba phatlalatsa pampiri ea lipatlisiso le ho lengole bakeng sa New England (nejm.
Phuputso ena ea bongaka e bontšitse hore semagllutide e ka fokotsa boima bo bakiloeng haholo e bakiloeng ke li-opioids), le ho ntlafatsa bokhoni ba bona ba ho nka karolo lipapaling. Ena hape ke lekhetlo la pele ke lekhetlo la pele mofuta o mocha oa lithethefatsi tsa ho fokotsa boima ba lithethefatsi, mohono o le mong oa bana ba hohelang, o tiisitsoe ho phekola ramatiki.
Poso: Feb-27-2025